iopamidol has been researched along with Minimal Disease, Residual in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Moriya, S; Nozaki, A; Numata, K; Okada, M; Oshima, T; Takebayashi, S; Takizawa, K; Tanaka, K | 1 |
| Altei, F; Catalano, O; Cusati, B; Esposito, M; Lobianco, R; Siani, A | 1 |
1 trial(s) available for iopamidol and Minimal Disease, Residual
| Article | Year |
|---|---|
Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Early Diagnosis; Female; Humans; Iopamidol; Liver Neoplasms; Male; Middle Aged; Neoplasm, Residual; Organoplatinum Compounds; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Ultrasonography | 2013 |
1 other study(ies) available for iopamidol and Minimal Disease, Residual
| Article | Year |
|---|---|
[Multiphasic spiral computed tomography in hepatocarcinoma. An evaluation following different percutaneous ablative procedures].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Contrast Media; Female; Humans; Hyperthermia, Induced; Iopamidol; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm, Residual; Tomography, X-Ray Computed | 1999 |